In:
International Journal of Cancer, Wiley, Vol. 138, No. 10 ( 2016-05-15), p. 2450-2465
Abstract:
What's new? Prognosis of patients with metastatic castration‐resistant prostate cancer (CRPC) remains poor due to the development of drug resistance. Here, the authors investigated the efficacy, toxicity and mechanism of action of the novel marine compound triterpene glycoside frondoside A (FrA) using CRPC cell lines in vitro and in vivo . They found that FrA inhibits human prostate cancer cells, including those resistant to docetaxel, abiraterone and enzalutamide. Remarkably, FrA simultaneously induces apoptosis and cell cycle arrest and suppresses pro‐survival autophagy. FrA also decreases local tumor growth and metastatic spread in vivo without significant toxicities, with immune‐modulating effects potentially contributing to the activity.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8